NASDAQ:CCXI - ChemoCentryx Stock Price, Forecast & News

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

ChemoCentryx Inc (NASDAQ:CCXI) posted its quarterly earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.06. The biopharmaceutical company earned $10.58 million during the quarter, compared to analyst estimates of $7.83 million. ChemoCentryx had a negative net margin of 143.30% and a negative return on equity of 88.76%. View ChemoCentryx's Earnings History.

ChemoCentryx is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for ChemoCentryx.

7 brokers have issued 1 year price objectives for ChemoCentryx's shares. Their forecasts range from $22.00 to $60.00. On average, they anticipate ChemoCentryx's share price to reach $44.67 in the next twelve months. This suggests a possible upside of 8.2% from the stock's current price. View Analyst Price Targets for ChemoCentryx.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ChemoCentryx.

News stories about CCXI stock have trended extremely negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ChemoCentryx earned a coverage optimism score of -4.5 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for ChemoCentryx.

ChemoCentryx saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 2,030,000 shares, a decline of 29.5% from the December 15th total of 2,880,000 shares. Based on an average daily volume of 1,170,000 shares, the days-to-cover ratio is presently 1.7 days. Currently, 5.0% of the company's shares are sold short. View ChemoCentryx's Current Options Chain.

Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer LP Unit (ET), Arrowhead Pharmaceuticals (ARWR), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Amicus Therapeutics (FOLD), Opko Health (OPK), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD) and Amarin (AMRN).

ChemoCentryx's stock is owned by many different of retail and institutional investors. Top institutional investors include Zurcher Kantonalbank Zurich Cantonalbank (0.00%). Company insiders that own ChemoCentryx stock include Geoffrey M Parker, James L Tyree, Markus J Cappel, Plc Glaxosmithkline, Pui San Kwan, Rajinder Singh, Susan M Kanaya and Thomas J Schall. View Institutional Ownership Trends for ChemoCentryx.

CCXI stock was purchased by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for ChemoCentryx.

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CCXI stock can currently be purchased for approximately $41.27.

ChemoCentryx has a market capitalization of $2.40 billion and generates $42.88 million in revenue each year. The biopharmaceutical company earns $-37,970,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. ChemoCentryx employs 76 workers across the globe.View Additional Information About ChemoCentryx.

The official website for ChemoCentryx is http://www.chemocentryx.com/.

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]